BioCentury
ARTICLE | Company News

Hookipa, Gilead partner to develop immunotherapies against HIV and HepB

June 8, 2018 3:11 PM UTC

Gilead Sciences Inc. (NASDAQ:GILD) gained exclusive, worldwide rights from Hookipa Biotech AG (Vienna, Austria) to use its TheraT and Vaxwave arenavirus-based vector technologies to develop immunotherapies for HBV and HIV infections.

Hookipa is to receive $10 million up front and will be eligible for more than $400 million in milestones, plus royalties. Gilead will provide all R&D funding. Hookipa will manufacture arenavirus-based vectors for Gilead and the companies will jointly develop therapies for HBV and HIV infections...